Patent application number | Description | Published |
20090270950 | Adaptive Interference Reduction During Telemetry - An implantable medical device has a first module for performing telemetry communications with another device and a second module for delivering a high voltage therapy to a patient. The first module is configured to detect a communication error, and the second module is configured to determine a need for the therapy and to charge a capacitor in response to the need for the therapy. The second module is configured to suspend the capacitor charging in response to receiving a notification from the first module corresponding to detecting a communication error. | 10-29-2009 |
20100198279 | TRANSCEIVER DUTY CYCLED OPERATIONAL MODE - A device, such as an IMD, operating in accordance with the techniques of this disclosure detects a telemetry configuration event and, in response to the telemetry configuration event, configures a telemetry module of the IMD to operate in a duty cycled operational mode. The duty cycled operational mode includes a plurality of intervals during which a transceiver of the telemetry module is powered down interleaved with intervals during which the transceiver is powered up, e.g., for transmitting or receiving communications over an established communication session. The power freed up during the intervals in which the transceiver is powered down may be allocated for use by other components of the IMD. The telemetry module maintains information regarding the established communication session during the plurality of intervals during which the transceiver is powered down such that transmit and receive operations may immediately begin during intervals in which the transceiver is powered up. | 08-05-2010 |
20100198280 | TRANSCEIVER DUTY CYCLED OPERATIONAL MODE - This disclosure describes an operational mode of a telemetry module. A device, such as a programming device, operating in accordance with the techniques of this disclosure determines that a transceiver of an implantable medical device is operating in a duty cycled operational mode that includes at least one interval during which the transceiver is powered down interleaved with intervals during which the transceiver is powered up, e.g., for transmitting or receiving communications over an established communication session. The programming device is configured to transmit information during the at least one interval in which the transceiver of the implantable medical device is powered down. Doing so ensures that the channel over which the programmer and implantable medical device communicate will not be usurped by another device. | 08-05-2010 |
20110046698 | RECOVERY OF A WIRELESS COMMUNICATION SESSION WITH AN IMPLANTABLE MEDICAL DEVICE - Techniques are described for recovery of an inadvertently lost communication session between an implantable medical device (IMD) and another device. For example, the IMD or other device may detect loss of the established communication session, attempt to reestablish the communication session on a same channel as the established communication session that was lost, and attempt to reestablish the communication session on an unspecified channel using a telemetry wakeup feature upon the failure to reestablish the communication session on the same channel. | 02-24-2011 |
20110184491 | WIRELESS COMMUNICATION WITH AN IMPLANTABLE MEDICAL DEVICE - The disclosure relates generally to wireless communication with an implantable medical device. An implantable medical device (IMD) may initiate the establishment of a communication session by sending a wakeup communication to an external device with which the IMD desires to communicate. The external device may operate in low power state (sometimes referred to as a sleep state or a low current state) in which the external device occasionally powers up telemetry circuitry to monitor for the wakeup communication from the IMD. Upon receiving the wakeup communication, the external device transitions from the low power state to a high power state to establish the communication session with the IMD. Operating the external device in the low power state when no communication session is established reduces the amount of power consumed by the external device when no telemetry is occurring, thus enabling the external device to be powered by a battery. | 07-28-2011 |
Patent application number | Description | Published |
20080227143 | STABILIZED HEMATOXYLIN - A stabilized hematoxylin composition is disclosed that includes one or both of a host compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process without undue degradation prior to use of the composition to stain a biological sample. Methods of using and making the stabilized composition also are disclosed. | 09-18-2008 |
20090017050 | EGFR ANTIGEN-BINDING MOLECULES AND USES THEREOF - Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms. | 01-15-2009 |
20100285025 | ANTIBODIES SPECIFIC FOR THE C-TERMINAL REGULATORY DOMAIN OF EGFR AND THEIR USE - Disclosed herein are antigen-binding molecules, such as antibodies, that specifically recognize a portion of the EGFR C-terminal (intracellular) regulatory domain that interacts with one or more regulatory molecules (such as Suppressor of Cytokine Signaling (“SOCS”) proteins). In certain normal or neoplastic cells and/or tissues, this region is inaccessible to the disclosed antigen-binding molecules. Thus, such antigen-binding molecules are useful at least to interrogate the regulated state of EGFR, predict the response of a cancer patient to EGFR inhibitor therapies, and/or predict the aggressiveness of neoplasms. | 11-11-2010 |
20120276584 | STABILIZED HEMATOXYLIN - A stabilized hematoxylin composition is disclosed that includes one or both of a host compound and an antioxidant. The disclosed composition exhibits sufficient stability to be utilized in an automated staining process without undue degradation prior to use of the composition to stain a biological sample. Methods of using and making the stabilized composition also are disclosed. | 11-01-2012 |